Trial Profile

A phase 1 study of IMC P115C in solid tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 27 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IMC P115C (Primary)
Indications Solid tumours
Focus Adverse reactions; First in man
Acronyms PRAME-A02-HLE

Most Recent Events

23 Dec 2024 Status changed from planning to recruiting, as per Immunocore media release.
23 Dec 2024 According to an Immunocore media release, the first patient has been dosed in the Phase 1 trial.
08 Aug 2024 According to an Immunocore media release, company submitted Clinical Trial Application (CTA) for IMC-P115C in the second quarter of 2024, which is currently under review.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com